Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus - PubMed (original) (raw)

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

G A Prince et al. J Virol. 1986 Mar.

Erratum in

• J Virol 1986 Jul;59(1):193

Abstract

Cotton rats previously inoculated with Formalin-inactivated respiratory syncytial virus (RSV) were challenged intranasally with live RSV to induce an enhancement of RSV disease similar to that observed after the administration of Formalin-inactivated RSV vaccine to human infants 20 years ago. Within 24 h after infection with RSV, cotton rats developed pulmonary lesions that reached a maximum by day 4. Histologically, the lesions resembled an experimental pulmonary Arthus reaction. An action of Formalin on RSV appears to be responsible for this effect, because live virus or virus heated in the absence of Formalin did not induce enhanced immunopathology. Selected epitopes on the fusion (F) or attachment (G) or both RSV surface glycoproteins that are involved in inducing neutralizing antibodies were modified to reduce or ablate their antigenicity. However, other epitopes on the F or G or both glycoproteins were not ablated by Formalin, because cotton rats inoculated parenterally with a Formalin-inactivated virus developed a high level of F and G antibodies measurable by an enzyme-linked immunosorbent assay. At this time, the effect of Formalin on RSV cannot be localized to either the F or G glycoprotein of RSV.

PubMed Disclaimer

Similar articles

• Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
  Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, Lawrence L, Zubak JJ, Chanock RM, Beeler JA, et al. Murphy BR, et al. Vaccine. 1989 Dec;7(6):533-40. doi: 10.1016/0264-410x(89)90278-8. Vaccine. 1989. PMID: 2692334
• Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
  Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. Murphy BR, et al. J Clin Microbiol. 1986 Aug;24(2):197-202. doi: 10.1128/jcm.24.2.197-202.1986. J Clin Microbiol. 1986. PMID: 3755730 Free PMC article.
• Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
  Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. Connors M, et al. Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3. Vaccine. 1992. PMID: 1609551
• Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
  Johnson TR, Graham BS. Johnson TR, et al. Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.

Cited by

• Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
  Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Spriggs MK, et al. J Virol. 1987 Nov;61(11):3416-23. doi: 10.1128/JVI.61.11.3416-3423.1987. J Virol. 1987. PMID: 2822951 Free PMC article.
• Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
  Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. Olmsted RA, et al. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7462-6. doi: 10.1073/pnas.83.19.7462. Proc Natl Acad Sci U S A. 1986. PMID: 3532115 Free PMC article.
• Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
  Maier C, Fuchs J, Irrgang P, Wißing MH, Beyerlein J, Tenbusch M, Lapuente D. Maier C, et al. Front Immunol. 2022 Jul 28;13:920256. doi: 10.3389/fimmu.2022.920256. eCollection 2022. Front Immunol. 2022. PMID: 36003372 Free PMC article.
• Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
  Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Murphy BR, et al. J Virol. 1988 Oct;62(10):3907-10. doi: 10.1128/JVI.62.10.3907-3910.1988. J Virol. 1988. PMID: 3047432 Free PMC article.
• Novel drugs targeting Toll-like receptors for antiviral therapy.
  Patel MC, Shirey KA, Pletneva LM, Boukhvalova MS, Garzino-Demo A, Vogel SN, Blanco JC. Patel MC, et al. Future Virol. 2014 Sep;9(9):811-829. doi: 10.2217/fvl.14.70. Future Virol. 2014. PMID: 25620999 Free PMC article.

References

1. 1. JAMA. 1967 Dec 18;202(12):1075-80 - PubMed
2. 1. Am J Epidemiol. 1969 Apr;89(4):405-21 - PubMed
3. 1. Am J Epidemiol. 1969 Apr;89(4):422-34 - PubMed
4. 1. Am J Epidemiol. 1969 Apr;89(4):435-48 - PubMed
5. 1. Am J Epidemiol. 1969 Apr;89(4):449-63 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database